Related papers: Three-Dimensional Amyloid-Beta PET Synthesis from …
The use of amyloid-beta (A$\beta$) clearance to support regulatory approvals of drugs in Alzheimer's disease (AD) remains controversial. We evaluate A$\beta$ as a potential trial-level surrogate endpoint for clinical function in AD using a…
Recent experiments with amyloid-beta (Abeta) peptide suggest that formation of toxic oligomers may be an important contribution to the onset of Alzheimer's disease. The toxicity of Abeta oligomers depends on their structure, which is…
Diffusion tensor imaging (DTI) provides crucial insights into the microstructure of the human brain, but it can be time-consuming to acquire compared to more readily available T1-weighted (T1w) magnetic resonance imaging (MRI). To address…
Cell image analysis is crucial in Alzheimer's research to detect the presence of A$\beta$ protein inhibiting cell function. Deep learning speeds up the process by making only low-level data sufficient for fruitful inspection. We first found…
In the recent years there have been a number of studies that applied deep learning algorithms to neuroimaging data. Pipelines used in those studies mostly require multiple processing steps for feature extraction, although modern…
The assessment of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) associated with brain changes remains a challenging task. Recent studies have demonstrated that combination of multi-modality imaging techniques can better…
In recent years, many papers have reported state-of-the-art performance on Alzheimer's Disease classification with MRI scans from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset using convolutional neural networks. However,…
Alzheimer's disease is estimated to affect around 50 million people worldwide and is rising rapidly, with a global economic burden of nearly a trillion dollars. This calls for scalable, cost-effective, and robust methods for detection of…
Alzheimer's Disease destroys brain cells causing people to lose their memory, mental functions and ability to continue daily activities. It is a severe neurological brain disorder which is not curable, but earlier detection of Alzheimer's…
Alzheimer's disease is a progressive neurodegenerative disorder in which mild cognitive impairment (MCI) marks a critical transition between aging and dementia. Neuroimaging modalities, such as structural MRI, provide biomarkers of this…
Neuropsychiatric symptoms (NPS) such as depression and apathy are common in Alzheimer's disease (AD) and often precede cognitive decline. NPS assessments hold promise as early detection markers due to their correlation with disease…
Early diagnosis of Alzheimer's disease (AD) is essential in preventing the disease's progression. Therefore, detecting AD from neuroimaging data such as structural magnetic resonance imaging (sMRI) has been a topic of intense investigation…
Alzheimer's disease (AD), a debilitating neurodegenerative disorder, remains one of the foremost public health challenges of our time. Despite decades of research, its etiology largely remains enigmatic. Recently, attention has turned to…
Detection of Alzheimer's Disease (AD) from neuroimaging data such as MRI through machine learning have been a subject of intense research in recent years. Recent success of deep learning in computer vision have progressed such research…
Recent evidence has shown that structural magnetic resonance imaging (MRI) is an effective tool for Alzheimer's disease (AD) prediction and diagnosis. While traditional MRI-based diagnosis uses images acquired at a single time point, a…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that predominantly affects the elderly population and currently has no cure. Magnetic Resonance Imaging (MRI), as a non-invasive imaging technique, is essential for the…
A large number of papers have introduced novel machine learning and feature extraction methods for automatic classification of AD. However, they are difficult to reproduce because key components of the validation are often not readily…
Characterizing a preclinical stage of Alzheimer's Disease (AD) via single imaging is difficult as its early symptoms are quite subtle. Therefore, many neuroimaging studies are curated with various imaging modalities, e.g., MRI and PET,…
Accumulation of amyloid beta proteins is a defining feature of Alzheimer's disease, and is usually accompanied by cerebrovascular pathology. Evidence suggests that amyloid beta and cerebrovascular pathology are mutually reinforcing; in…
Ultra-high resolution 7 tesla (7T) magnetic resonance imaging (MRI) provides detailed anatomical views, offering better signal-to-noise ratio, resolution and tissue contrast than 3T MRI, though at the cost of accessibility. We present an…